Biohaven Ltd. (BHVN) Research

Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.

Market snapshot

Symbol
BHVN
Price
$13.57
Day change
-0.37%
Market cap
$1.4B
P/E ratio
-3.09x
52-week range
7.48-18.566
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$17.60

Peer companies

  • AbCellera Biologics Inc. (ABCL)
  • Celldex Therapeutics, Inc. (CLDX)
  • Immunocore Holdings plc (IMCR)
  • Immunome, Inc. (IMNM)
  • Intellia Therapeutics, Inc. (NTLA)
  • Pharvaris N.V. (PHVS)
  • Sionna Therapeutics, Inc. (SION)
  • Vera Therapeutics, Inc. (VERA)

Recent insider activity

  • Mehta Kishan — A-Award (68693 shares) on 2026-04-28
  • Bailey Gregory — A-Award (68693 shares) on 2026-04-28
  • Heffernan Michael Thomas — A-Award (68693 shares) on 2026-04-28
  • Antonijevic Irina — A-Award (68693 shares) on 2026-04-28
  • CHILDS JOHN W — A-Award (68693 shares) on 2026-04-28

Open Biohaven Ltd. (BHVN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.